Zonagen/Schering-Plough Vasomax
Executive Summary
"Not approvable" letter expected for the oral erectile dysfunction treatment. The companies plan to submit results of Schering's ongoing clinical trials to supplement the NDA. A June advisory committee review of the current data was deferred. The companies believe the additional data, to be submitted in 2000, will differentiate Vasomax (phentolamine) from Pfizer's Viagra (sildenafil). The NDA was submitted in July 1998